CR11529A - Compuestos de cicloalquiloxi y heterocicloalquilopiridina como moduladores del receptor de h3 de histamina - Google Patents

Compuestos de cicloalquiloxi y heterocicloalquilopiridina como moduladores del receptor de h3 de histamina

Info

Publication number
CR11529A
CR11529A CR11529A CR11529A CR11529A CR 11529 A CR11529 A CR 11529A CR 11529 A CR11529 A CR 11529A CR 11529 A CR11529 A CR 11529A CR 11529 A CR11529 A CR 11529A
Authority
CR
Costa Rica
Prior art keywords
histamine
receptor
cycloalkyloxy
compounds
heterocycloalkylpyridine
Prior art date
Application number
CR11529A
Other languages
English (en)
Spanish (es)
Inventor
A Letavic Michael
M Stocking Emily
Original Assignee
Helsinn Healthcare Sa
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40297867&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR11529(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Helsinn Healthcare Sa, Janssen Pharmaceutica Nv filed Critical Helsinn Healthcare Sa
Publication of CR11529A publication Critical patent/CR11529A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Addiction (AREA)
  • Child & Adolescent Psychology (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CR11529A 2007-11-20 2010-06-21 Compuestos de cicloalquiloxi y heterocicloalquilopiridina como moduladores del receptor de h3 de histamina CR11529A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US98924607P 2007-11-20 2007-11-20

Publications (1)

Publication Number Publication Date
CR11529A true CR11529A (es) 2012-10-25

Family

ID=40297867

Family Applications (1)

Application Number Title Priority Date Filing Date
CR11529A CR11529A (es) 2007-11-20 2010-06-21 Compuestos de cicloalquiloxi y heterocicloalquilopiridina como moduladores del receptor de h3 de histamina

Country Status (22)

Country Link
US (1) US8883776B2 (cg-RX-API-DMAC7.html)
EP (1) EP2222664B1 (cg-RX-API-DMAC7.html)
JP (1) JP5498390B2 (cg-RX-API-DMAC7.html)
KR (1) KR101546712B1 (cg-RX-API-DMAC7.html)
CN (2) CN101868454A (cg-RX-API-DMAC7.html)
AR (2) AR069387A1 (cg-RX-API-DMAC7.html)
AU (1) AU2008326561B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0820481A2 (cg-RX-API-DMAC7.html)
CA (1) CA2706328C (cg-RX-API-DMAC7.html)
CL (1) CL2008003465A1 (cg-RX-API-DMAC7.html)
CO (1) CO6210700A2 (cg-RX-API-DMAC7.html)
CR (1) CR11529A (cg-RX-API-DMAC7.html)
EA (1) EA018582B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP10010190A (cg-RX-API-DMAC7.html)
MX (1) MX2010005488A (cg-RX-API-DMAC7.html)
MY (1) MY158253A (cg-RX-API-DMAC7.html)
NI (1) NI201000086A (cg-RX-API-DMAC7.html)
NZ (1) NZ584998A (cg-RX-API-DMAC7.html)
TW (1) TWI491604B (cg-RX-API-DMAC7.html)
UA (1) UA103468C2 (cg-RX-API-DMAC7.html)
WO (1) WO2009067401A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201004334B (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0324159D0 (en) 2003-10-15 2003-11-19 Glaxo Group Ltd Novel compounds
US8288389B2 (en) * 2007-09-06 2012-10-16 Glaxo Group Limited Piperazine derivative having affinity for the histamine H3 receptor
US20090318380A1 (en) 2007-11-20 2009-12-24 Pharmasset, Inc. 2',4'-substituted nucleosides as antiviral agents
BRPI0913057A2 (pt) * 2008-05-08 2015-10-13 Evotec Ag azetidinas e ciclobutanos como antagonistas de receptor de histamina h3
PL3216784T3 (pl) * 2009-03-18 2019-07-31 Janssen Pharmaceutica Nv Sposób wytwarzania modulatorów receptorów histaminowych H3
CN102638979A (zh) * 2009-09-21 2012-08-15 范德比尔特大学 作为mGluR5 正变构调节剂的邻苄基烟酰胺
US20140142070A1 (en) 2011-07-07 2014-05-22 Janssen R&D Ireland Darunavir combination formulations

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE817911C (de) 1947-12-16 1951-10-22 Chem Fab Tempelhof Preuss & Te Verfahren zur Darstellung von in 6-Stellung basisch substituierten Pyridin-3-carbonsaeureamiden
BE726551A (cg-RX-API-DMAC7.html) 1968-01-22 1969-06-16
ES436109A1 (es) 1974-04-04 1977-01-01 Christiaens Sa A Procedimiento para la preparacion de nuevos derivados de pi-ridina.
EP0089765A3 (en) 1982-03-17 1984-05-23 Smith Kline & French Laboratories Limited Pyridine derivatives
GB8311443D0 (en) 1983-04-27 1983-06-02 Smith Kline French Lab Chemical compounds
GB8320505D0 (en) 1983-07-29 1983-09-01 Smith Kline French Lab Chemical compounds
GB8332091D0 (en) 1983-12-01 1984-01-11 Smith Kline French Lab Chemical compounds
JPS61149119A (ja) 1984-12-22 1986-07-07 旭光学工業株式会社 検眼用試験枠
US4792547A (en) 1985-12-26 1988-12-20 Hokuriku Pharmaceutical Co., Ltd. Pyrazine-2-carboxamide derivatives useful in treating allergic disease
JPH0637595B2 (ja) 1986-08-06 1994-05-18 日本ペイント株式会社 陰極電着塗料組成物
GB9025828D0 (en) 1990-11-28 1991-01-09 Shell Int Research Herbicidal carboxamide derivatives
JP3354271B2 (ja) 1993-02-25 2002-12-09 三共株式会社 ピリジルオキシアミド誘導体
EP0761654B1 (en) 1995-08-24 2003-06-18 Basf Aktiengesellschaft Isoxazole- and isothiazole-5-carboxamide derivatives, their preparation and their use as herbicides
WO1997024329A1 (en) 1995-12-28 1997-07-10 Kureha Kagaku Kogyo Kabushiki Kaisha Process for producing pyridinecarboxamides or thiocarboxamides
TNSN97092A1 (ar) 1996-09-18 1999-12-31 Agouron Pharma مثبطات انزيم بروتيني فلزي وتركيبات صيدلانية تحتوي على تلك المثبتطات واستخدامها الصيدلاني وطرق ومركبات وسيطة مفيدة لتحضير التركيبات المذكورة.
US6967196B1 (en) 1999-02-26 2005-11-22 Bristol-Myers Squibb Company Sulfonamide compounds and uses thereof
MXPA01011905A (es) 1999-05-21 2004-03-19 Biovitrum Ab Compuestos novedosos, su uso y preparacion.
US6399607B1 (en) 1999-07-02 2002-06-04 Research Foundation-State University Of New York Aminomethylene amide analogs of pyrazinamide with intracellular antimycobacterial activity against pyrazinamide-resistant mycobacteria combined with a rifamycin
DE10023492A1 (de) 2000-05-09 2001-11-22 Schering Ag Aza- und Polyazanthranylamide und deren Verwendung als Arzneimittel
US6645990B2 (en) 2000-08-15 2003-11-11 Amgen Inc. Thiazolyl urea compounds and methods of uses
US6995162B2 (en) 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
JP2002322163A (ja) 2001-04-20 2002-11-08 Sumitomo Pharmaceut Co Ltd ピペラジン誘導体
WO2002100399A1 (en) * 2001-06-12 2002-12-19 Elan Pharmaceuticals, Inc. Macrocycles useful in the treatment of alzheimer's disease
EP1396487B1 (en) 2001-06-15 2008-12-10 Astellas Pharma Inc. Phenylpyridine carbonyl piperazine derivative
US7208497B2 (en) 2001-07-02 2007-04-24 Novo Nordisk A/S Substituted piperazines and diazepanes
EP1421071B1 (en) 2001-07-02 2009-11-18 High Point Pharmaceuticals, LLC Substituted piperazine and diazepane derivaives as histamine h3 receptor modulators
AU2002363176B2 (en) 2001-11-01 2008-09-25 Janssen Pharmaceutica N.V. Heteroaryl amines as glycogen synthase kinase 3Beta inhibitors (GSK3 inhibitors)
CA2463821A1 (en) 2001-11-01 2003-05-08 Janssen Pharmaceutica N.V. Amide derivatives as glycogen synthase kinase 3-beta inhibitors
AU2003203148A1 (en) 2002-02-05 2003-09-02 High Point Pharmaceuticals, Llc Novel aryl- and heteroarylpiperazines
GB0206219D0 (en) 2002-03-15 2002-05-01 Ferring Bv Non-Peptide GnRH antagonists
AU2003226094A1 (en) 2002-03-27 2003-10-13 Smithkline Beecham Corporation Compounds and methods
US20040014744A1 (en) 2002-04-05 2004-01-22 Fortuna Haviv Substituted pyridines having antiangiogenic activity
GB0209715D0 (en) 2002-04-27 2002-06-05 Astrazeneca Ab Chemical compounds
EP1388535A1 (en) 2002-08-07 2004-02-11 Aventis Pharma Deutschland GmbH Acylated arylcycloalkylamines and their use as pharmaceuticals
US20040110802A1 (en) 2002-08-23 2004-06-10 Atli Thorarensen Antibacterial benzoic acid derivatives
GB0224084D0 (en) 2002-10-16 2002-11-27 Glaxo Group Ltd Novel compounds
AU2003274053A1 (en) 2002-10-22 2004-05-13 Glaxo Group Limited Aryloxyalkylamine derivates as h3 receptor ligands
DE60330269D1 (de) 2002-10-23 2010-01-07 Janssen Pharmaceutica Nv Piperazinyl- und diazapanylbenzamide und-benzothioamide
US7332508B2 (en) 2002-12-18 2008-02-19 Novo Nordisk A/S Substituted homopiperidine, piperidine or pyrrolidine derivatives
AU2004257025B9 (en) 2003-06-27 2010-05-27 Msd K.K. Heteroaryloxy nitrogenous saturated heterocyclic derivative
RU2006101452A (ru) 2003-07-29 2006-06-27 Ново Нордиск А/С (DK) Пиридазинил-пиперазины и их применение в качестве лигандов h3 гистаминового рецептора
WO2005023247A1 (en) 2003-09-03 2005-03-17 Smithkline Beecham Corporation Compounds and methods
GB0324159D0 (en) 2003-10-15 2003-11-19 Glaxo Group Ltd Novel compounds
EP1761496A2 (en) 2004-03-31 2007-03-14 Janssen Pharmaceutica N.V. Non-imidazole heterocyclic compounds as histamine h3-receptor ligands
AU2005231375A1 (en) 2004-03-31 2005-10-20 Janssen Pharmaceutica, N.V. Non-imidazole heterocyclic compounds as histamine H3 receptor modulators
GB0514812D0 (en) * 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
EP1948607B1 (en) 2005-09-16 2010-04-07 Janssen Pharmaceutica, N.V. Cyclopropyl amines as modulators of the histamine h3 receptor
CA2634250A1 (en) * 2005-12-21 2007-07-05 Schering Corporation Phenoxypiperidines and analogs thereof useful as histamine h3 antagonists
CA2634847A1 (en) * 2005-12-21 2007-07-05 Schering Corporation Substituted aniline derivatives useful as histamine h3 antagonists
EP1994022A2 (en) 2006-03-15 2008-11-26 Wyeth a Corporation of the State of Delaware N-substituted-azacyclylamines as histamine-3 antagonists
MX2008015365A (es) * 2006-05-30 2008-12-16 Janssen Pharmaceutica Nv Compuestos de piridil amida sustituidos como moduladores del receptor h3 de la histamina.
EP2038269A1 (en) * 2006-06-29 2009-03-25 Janssen Pharmaceutica N.V. Substituted benzamide modulators of the histamine h3 receptor
US20090131417A1 (en) * 2007-11-20 2009-05-21 Letavic Michael A Substituted pyridyl amide compounds as modulators of the histamine h3 receptor

Also Published As

Publication number Publication date
EA201070637A1 (ru) 2010-12-30
WO2009067401A1 (en) 2009-05-28
AR110977A2 (es) 2019-05-22
NI201000086A (es) 2011-03-17
AU2008326561B2 (en) 2013-12-05
EP2222664A1 (en) 2010-09-01
KR101546712B1 (ko) 2015-08-24
EP2222664B1 (en) 2014-10-29
CA2706328C (en) 2016-04-19
JP5498390B2 (ja) 2014-05-21
CN105712977A (zh) 2016-06-29
CN101868454A (zh) 2010-10-20
UA103468C2 (ru) 2013-10-25
MX2010005488A (es) 2010-06-01
JP2011503233A (ja) 2011-01-27
MY158253A (en) 2016-09-30
TWI491604B (zh) 2015-07-11
CO6210700A2 (es) 2010-10-20
CL2008003465A1 (es) 2009-03-06
HK1147994A1 (en) 2011-08-26
ECSP10010190A (es) 2010-06-29
NZ584998A (en) 2012-08-31
US8883776B2 (en) 2014-11-11
TW200936579A (en) 2009-09-01
ZA201004334B (en) 2011-10-26
KR20100098636A (ko) 2010-09-08
US20090131415A1 (en) 2009-05-21
AU2008326561A1 (en) 2009-05-28
BRPI0820481A2 (pt) 2015-06-16
CA2706328A1 (en) 2009-05-28
EA018582B1 (ru) 2013-09-30
AR069387A1 (es) 2010-01-20
CN105712977B (zh) 2021-06-29

Similar Documents

Publication Publication Date Title
CR9891A (es) Ciclopropil aminas como moduladores del receptor de histamina h3
NI200800314A (es) Compuestos de amidas de piridil sustituidos como moduladores del receptor de histamina h3
CR20110477A (es) Inhibidores de enzimas de proteina cinasa activadas por mitogeno p38
EA201001372A1 (ru) Формы рифаксимина и их применение
CR11529A (es) Compuestos de cicloalquiloxi y heterocicloalquilopiridina como moduladores del receptor de h3 de histamina
BRPI0808775A2 (pt) compostos e composições como moduladores de atividade de gpr119
HN2007015177A (es) Derivados de triazolopirazina
CR11027A (es) Modulares 2-aminopirimidina del receptor de histamina h4
MX2009009415A (es) Compuestos de tetrahidroisoquinolina como moduladores del receptor h3 de la histamina.
UY32057A (es) Compuestos triazolopiridina como inhibidores de pim cinasa
SV2010003662A (es) Derivados de azetidina y ciclobutano como inhibidores de jak ref. x-19081
UY30479A1 (es) Moduladores de benzofuro- y benzotienopirimidina del receptor de histamina h4
NI200800260A (es) Benzoimidazole - 2 - il pirimidinas y pirazinas como moduladores del receptor de histamina h4
HN2011002809A (es) Compuestos de vinil indazolilo
CR20110029A (es) Moduladores de diamino-piridina, pirimidina, y piridazina del receptor h4 de histamina
CL2009000402A1 (es) Compuestos derivados de 2-amino-acetamida sustituida; composicion farmaceutica; utiles en el tratamiento de enfermedades pulmonares, enfermedad reumatica, enfermedad autoinmune, entre otras.
CL2008002268A1 (es) Compuestos derivados de amidas, moduladores del receptor taar1; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como depresion, ansiedad, estres, entre otros.
CR9791A (es) Compuestos de pirimidina como moduladores de receptor de serotonina
CR10060A (es) 3-aminociclopentanocarboxamidas como moduladores de receptores de quimioquinas
GT201500243A (es) Moduladores benzoimidazol-2-il pirimidinas del receptor h4 de histamina
UY34043A (es) Isoxazolinas como agentes terapéuticos
PA8827501A1 (es) Pirrolidin amidas sustituidas como moduladores del receptor histamina h3
UY31717A1 (es) (pirazolilcarbonil) imidazolidinonas sustituidas y su uso
GT200600156A (es) Compuestos heteroaromaticos acilaminobiciclicos y sus usos
CR20110012A (es) Compuestos de fenantrenona, composiciones y métodos

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)